Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1B Study

ReutersJun 23, 2025 11:05 AM

June 23 (Reuters) - Arrivent Biopharma Inc AVBP.O:

ARRIVENT ANNOUNCES POSITIVE INTERIM FIRMONERTINIB MONOTHERAPY DATA FROM GLOBAL PHASE 1B STUDY IN EGFR PACC MUTANT NON-SMALL CELL LUNG CANCER AND PLANS TO ADVANCE INTO A GLOBAL PIVOTAL STUDY
ARRIVENT BIOPHARMA- ENROLLMENT OF FIRST PATIENT IN A RANDOMIZED, GLOBAL PIVOTAL PHASE 3 STUDY IN FIRST-LINE PACC PATIENTS EXPECTED IN H2 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

TradingKey - Intel Corporation (NASDAQ: INTC) and Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) are two companies that play crucial roles in the semiconductor market; however, they each have completely different business models.

Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

TradingKey - Since April, the precious metals market has continued the weakness seen in March. Spot gold recorded a cumulative decline of nearly 2% in April, while spot silver briefly fell below the $70 mark.

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

TradingKey - SanDisk (SNDK) now represents not just a name for many consumers, but also an investment play on one of the fastest-growing sectors in technology – Artificial Intelligence.

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

TradingKey - On April 29 (ET), Microsoft (MSFT) released its Q3 FY2026 results after the bell. Both revenue and profit exceeded expectations, with Azure growth returning to 40% and annualized AI revenue surpassing $37 billion. Despite this, shares fell more than 3% in after-hours trading and ended t

$11.4 Billion Revenue Vs. 1.75 Trillion Valuation: Can Starlink Support SpaceX IPO?

TradingKey - On April 14, The Information disclosed a set of unpublished financial data: Starlink's satellite internet business revenue grew 50% year-over-year in 2025 to $11.4 billion, with EBITDA reaching $7.2 billion and an adjusted margin as high as 63%.

Featured Tools